Drugs / SHR9549
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03596658 | Jul 2018 → Oct 2019 | estrogen-receptor positive breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR9549 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03596658 ↗ |
| Route | Oral | “SHR9549 administered orally” NCT03596658 ↗ |